Last updated on August 2019

A Study to Test the Safety of the Investigational Drug Loxo-195 in Children and Adults That May Treat Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Thyroid Adenoma | Colorectal Cancer | Lung Neoplasm | Ovarian Cancer | Invasive Ductal Breast Carcinoma | Head and Neck Squamous Cell Carcinoma | Biliary neoplasm | Nerve Sheath Tumors | Bronchial Neoplasm | Pancreatic Cancer | Central Nervous System Neoplasms | Thoracic Neoplasms | Fibrosarcoma | Neoplasms | Intestinal Cancer | Renal Cell Carcinoma | Uterine Cancer | Breast Secretory Carcinoma | Solid Tumors Harboring NTRK Fusion | Bronchogenic Carcinoma | Respiratory Tract Neoplasm | Skin Carcinoma | salivary gland cancer | Glioblastoma Multiforme | melanoma | Infantile Fibrosarcoma | gastrointestinal stromal tumor | Nerve Tissue | Malignant neoplasm of brain | Astrocytoma | Nevi and Melanomas | Cholangiocarcinoma | gliomas pontine | Non-Small Cell Lung Cancer | Mesoblastic Nephroma | Bile duct carcinoma | Sarcoma | skin cancer
  • Age: Between 1 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Advanced solid tumor for which, in the opinion of the investigator, no other standard therapy offers greater benefit.
  • A solid tumor diagnosis in the setting of:
  • a) a documented NTRK fusion and a clinical history of relapse following a response to a prior TRK inhibitor
  • b) a documented NTRK fusion unresponsive to a prior TRK inhibitor
  • c) a documented NTRK fusion and a clinical history of intolerance to a prior TRK inhibitor
  • NTRK gene fusions will be identified in a CLIA-certified (or equivalent) laboratory. Patients with infantile fibrosarcoma (IFS) or congenital mesoblastic nephroma (CMN) may be enrolled based on an ETV6+ FISH test without identifying NTRK3
  • Performance Status: Eastern Cooperative Oncology Group (ECOG) score 3 (age 16 years) or Lansky Performance Score (LPS) 40% (age < 16 years). If enrolled with primary CNS tumor to be assessed by RANO, Karnofsky Performance Score (KPS) (age 16 years) or LPS (age < 16 years) 50%.
  • Life expectancy > 4 weeks.
  • Adequate hematologic, hepatic and renal function.
  • Patients with stable CNS primary tumor, brain metastases, or treated spinal cord compression are eligible if neurological symptoms have been stable for 7 days prior to the first dose of LOXO-195
  • Ability to receive study drug orally or by enteral administration

Exclusion Criteria:

  • Concurrent treatment with a strong CYP3A4 inhibitor or inducer or drugs associated with QT prolongation.
  • Clinically significant active cardiovascular disease or history of myocardial infarction within 3 months prior to planned start of LOXO-195, or prolongation of QT interval corrected for heart rate (QTc interval) >480 milliseconds within past 6 months
  • Major surgery within 7 days of enrollment
  • Uncontrolled systemic bacterial, fungal or viral infection.
  • Pregnancy or lactation.
  • Known hypersensitivity to LOXO-195 or Ora-Sweet SF and OraPlus for patients receiving liquid formulation.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.